Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Прерывание беременности в I триместре с помощью препарата "Мифепристон"
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Абашин В.Г. Прерывание беременности в I триместре препаратом мифегин. Акуш. и гин. 2000; 6: 40–3.
2. Кулаков В.И Планирование семьи в России: идеология и стратегия. Планирование семьи. 1997; 1: 12–3.
3. HeikinheimoO. Clinical pharmacokinetics of mifepristone. Clin pharmakokinet 1997; 33: 7–17.
4. McDonnel DP. Unraveling the human progesterone receptor signal yransduction pathways (insight into antiprogestin action. Trends Enducrinol Metah 1995; 6: 133–8.
5. Urquhart DR, Templeton AA, Shinewi F. The efficacy and tolerance of mifepristone and prostaglandin in termination of pregnancy of less than 63 days gestation: UK Multicentre Studi. Final Results. Contraception 1997; 55: 1–5.
6. WHO. Pregnancy termination with mifepristone and gemeprost: a multicentre comparison between repeated doses and a single dose of mifepristone. Fertil Sferil 1991; 56: 32–40.
7. Brogden RN, Goa KL, Faulds D. Mifepristone: a review of its pharmacodynamic and pharmacokinetics properties and therapeutic potencial. Drug 1993; 45: 384–409.
8. Aubeny E, Peyron R, Tuprin CL et al. Termination of early pregnancy (up to 63 days of amenorrhea) with mifepristone and increasing doses of misoprostol. Int J Fertil Menopausal Stud 1995; 40 (Suppl. 2): 85–91.
9. Caristed-Duke Y et al. The steroid/thyroid Hormone Receptor Family and Gene Regulation. Basel Boston, 1987.
10. Spitz IM, Bardin CW, Benton L, Robbins A. Early pregnancy termination with mifepristone and the orally active prostaglandin misoprostol. N Engl J Med 1998; 176: 1241–7.
11. Aubeny E, Chatellier G. A randomized comparison of mifepristone and self-administered oral or vaginal misoprostol for early abortion. Eur J Contracepl Reprod. Health care 2000; 5: 171–6.
12. Гусева Е.Н., Абрамченко В.В., Курчишвили В.И., Карпов А.Б. Применение мифепристона для искусственного прерывания беременности ранних сроков. Акуш. и гин. 2004; 5: 41–2.
13. Robbins A, Spitz IM. Mifepristone: clinical pharmacology. Clin Obstet Gynecol 1996; 39: 436–50.
14. Spitz M, Bardin CW. Mifepristone (RU486) – a modulator ofprogestin and antiglucocorticoid action. N Engl J Med 1993; 329: 404–12.
15. Spitz M, Croxatto HB, Robbins A. Antiprogestin: mechanism of action and contraceptive potencial. Annu Rev Pharmacol Toxicol 1996; 36: 47–81.
16. WHO. Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomised trial. Br J Obstet Gynaecol 2000; 107: 524–30.
17. Schaff EA, Eisinger SH, Stadalius LS et al. Vaginal misoprostol administered at home after mifepristone (RU486) for abortion. Fam Pracl 1997; 44: 353–40.
18. Bygdeman M, Swahn ML. Progesterone receptor blocade – effect on uterine contractility and early pregnancy. Contraception 1985; 32: 45–51.
21. WHO. Termination of pregnancy with reduced doses mifepristone. BMJ 1993; 307: 532–7.
22. Winikoff B, Sivin I, Coyaji KJ, Caberaz E et al. The acceptability of medical abortion in China, Cuba and India. Int Fam Plan Perspect 1997; 23: 73–8.
2. Кулаков В.И Планирование семьи в России: идеология и стратегия. Планирование семьи. 1997; 1: 12–3.
3. HeikinheimoO. Clinical pharmacokinetics of mifepristone. Clin pharmakokinet 1997; 33: 7–17.
4. McDonnel DP. Unraveling the human progesterone receptor signal yransduction pathways (insight into antiprogestin action. Trends Enducrinol Metah 1995; 6: 133–8.
5. Urquhart DR, Templeton AA, Shinewi F. The efficacy and tolerance of mifepristone and prostaglandin in termination of pregnancy of less than 63 days gestation: UK Multicentre Studi. Final Results. Contraception 1997; 55: 1–5.
6. WHO. Pregnancy termination with mifepristone and gemeprost: a multicentre comparison between repeated doses and a single dose of mifepristone. Fertil Sferil 1991; 56: 32–40.
7. Brogden RN, Goa KL, Faulds D. Mifepristone: a review of its pharmacodynamic and pharmacokinetics properties and therapeutic potencial. Drug 1993; 45: 384–409.
8. Aubeny E, Peyron R, Tuprin CL et al. Termination of early pregnancy (up to 63 days of amenorrhea) with mifepristone and increasing doses of misoprostol. Int J Fertil Menopausal Stud 1995; 40 (Suppl. 2): 85–91.
9. Caristed-Duke Y et al. The steroid/thyroid Hormone Receptor Family and Gene Regulation. Basel Boston, 1987.
10. Spitz IM, Bardin CW, Benton L, Robbins A. Early pregnancy termination with mifepristone and the orally active prostaglandin misoprostol. N Engl J Med 1998; 176: 1241–7.
11. Aubeny E, Chatellier G. A randomized comparison of mifepristone and self-administered oral or vaginal misoprostol for early abortion. Eur J Contracepl Reprod. Health care 2000; 5: 171–6.
12. Гусева Е.Н., Абрамченко В.В., Курчишвили В.И., Карпов А.Б. Применение мифепристона для искусственного прерывания беременности ранних сроков. Акуш. и гин. 2004; 5: 41–2.
13. Robbins A, Spitz IM. Mifepristone: clinical pharmacology. Clin Obstet Gynecol 1996; 39: 436–50.
14. Spitz M, Bardin CW. Mifepristone (RU486) – a modulator ofprogestin and antiglucocorticoid action. N Engl J Med 1993; 329: 404–12.
15. Spitz M, Croxatto HB, Robbins A. Antiprogestin: mechanism of action and contraceptive potencial. Annu Rev Pharmacol Toxicol 1996; 36: 47–81.
16. WHO. Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomised trial. Br J Obstet Gynaecol 2000; 107: 524–30.
17. Schaff EA, Eisinger SH, Stadalius LS et al. Vaginal misoprostol administered at home after mifepristone (RU486) for abortion. Fam Pracl 1997; 44: 353–40.
18. Bygdeman M, Swahn ML. Progesterone receptor blocade – effect on uterine contractility and early pregnancy. Contraception 1985; 32: 45–51.
21. WHO. Termination of pregnancy with reduced doses mifepristone. BMJ 1993; 307: 532–7.
22. Winikoff B, Sivin I, Coyaji KJ, Caberaz E et al. The acceptability of medical abortion in China, Cuba and India. Int Fam Plan Perspect 1997; 23: 73–8.
Авторы
А.А.Куземин, Д.В.Жердев
ГУ Научный центр акушерства, гинекологии и перинатологии
(дир. – акад. РАМН, проф. В.И.Кулаков) РАМН, Москва
ГУ Научный центр акушерства, гинекологии и перинатологии
(дир. – акад. РАМН, проф. В.И.Кулаков) РАМН, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.